Treace Medical Concepts (TMCI) Liabilities and Shareholders Equity (2020 - 2026)

Treace Medical Concepts (TMCI) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $184.1 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 10.56% year-over-year to $184.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $777.7 million (down 9.77% YoY) and the FY2025 annual result came in at $190.6 million, down 12.21% from the prior year.
• Liabilities and Shareholders Equity declined to $184.1 million in Q1 2026, from $190.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $251.9 million in Q4 2023 to a low of $146.5 million in Q1 2022.
• A 5-year average of $205.5 million and a median of $206.4 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 291.93% — and 2025, when it fell 15.19%.
• Tracing TMCI's Liabilities and Shareholders Equity over 5 years: stood at $159.0 million in 2022, then soared by 58.41% to $251.9 million in 2023, then fell by 13.82% to $217.1 million in 2024, then dropped by 12.21% to $190.6 million in 2025, then declined by 3.4% to $184.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $184.1 million (Q1 2026), $190.6 million (Q4 2025), and $196.6 million (Q3 2025), per Business Quant data.